Natco Pharma launches Hepatitis C drug in Nepal

Written by Meghna A Singhania Published On 2015-10-29T12:50:24+05:30 | Updated On 29 Oct 2015 12:50 PM IST

Natco Pharma launches Hepatitis C drug in Nepal

New Delhi: Natco Pharma today said it has launched generic Hepcinat LP, which is in the treatment of chronic hepatitis C infection in adults, in Nepal.

NATCO priced its generic medicine, Hepcinat LP, at Rs 25,000 for a bottle of 28 tablets in Nepal, the company said in a filing to the BSE.

Hepcinat LP is generic version of Ledipasvir and Sofosbuvir combination and is used in the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.

Natco had signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015, to manufacture and sell generic versions of its chronic hepatitis C medicines, including generic version of HARVONI, in India and other 100 developing countries.

Meghna A Singhania

Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751